Alimera Sciences, Inc. (NASDAQ:ALIM) is seeing significant growth in short interest

Alimera Sciences, Inc. ( NASDAQ:ALIM – Get Free Report ) was the target of a big gain in short interest in May. As of May 31, short interest was 127,000 shares, an increase of 22.2% from the total of 103,900 shares as of May 15. With average trading volume of 98,200 shares, the short interest rate is currently 1.3 days.

The Wall Street analyst concludes

ALIM has been the subject of several recent research reports. On Monday, March 25, Maxim Group acquired shares of Alimera Sciences in a report. They gave the company a “buy” rating and a target price of $10.00. On Tuesday, April 30, StockNews.com downgraded Alimera Sciences from “buy” to “hold.” Ultimately, HC Wainwright maintained a “buy” rating and set a $6.00 price target for shares of Alimera Sciences in a research note on Thursday, May 16.

Check out our latest analysis for ALIM

Alimera Sciences stock performance

On Friday, ALIM opened at $3.17. The company has a fifty-day moving average price of $3.34 and a 200-day moving average price of $3.63. Alimera Sciences has a 1-year low of $2.60 and a 1-year high of $4.38. The market value of the company’s shares is $166.08 million, the P/E ratio is -2.02 and the beta coefficient is 1.14. The company has a debt to equity ratio of 1.71, a current ratio of 2.62 and a quick ratio of 2.51.

Alimera Sciences (NASDAQ:ALIM – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the analyst consensus estimate of ($0.04) by ($0.08). Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. The company had revenue of $23.01 million for the quarter, compared to analyst estimates of $23.72 million. During the same quarter last year, the company saw EPS ($0.71). Equity research analysts predict that Alimera Sciences will post earnings per share of -0.13 for the current year.

Alimera Sciences Institutional Trading

Several institutional investors have recently bought and sold shares of ALIM. Fifth Lane Capital LP acquired a new position in shares of Alimera Sciences during the first quarter worth approximately $83,000. Hillsdale Investment Management Inc. acquired a new position in Alimera Sciences during the first quarter worth $169,000. Ancora Advisors LLC acquired a new stake in shares of Alimera Sciences during the first quarter worth approximately $915,000. Worth Venture Partners LLC acquired a new stake in shares of Alimera Sciences during the third quarter worth approximately $1,840,000. Finally, in the first quarter, Vanguard Group Inc. increased its shares in Alimera Sciences shares by 61.1%. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares in the last quarter. 99.83% of the shares are owned by institutional investors and hedge funds.

Alimera Sciences company profile

(Get the free report)

Alimera Sciences, Inc, a pharmaceutical company, develops and markets prescription ophthalmic retinal medications. It operates in the United States, International and Operating Expense segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant used to treat diabetic macular edema (DME), a retinal disease that affects people with diabetes and can lead to severe vision loss and blindness; and to prevent recurrence of recurrent non-infectious uveitis of the posterior segment (NIU-PS).

The Wall Street analyst concludes

Alimera Sciences stock performance

Alimera Sciences Institutional Trading

Alimera Sciences company profile

Further reading